@FiercePharma: China's animal health market is growing doggone fast. Bayer, Sanofi, etc. aim to take advantage--Bloomberg. Report | Follow @FiercePharma
> GlaxoSmithKline ($GSK) is preparing to shutter a factory in western India after all its workers there accepted early retirement. Report
> Hospira ($HSP) pulled one lot of its hydromorphone painkiller after reports that its injection device might be overfilled, increasing the risk of overdose. Report
> Roche ($RHHBY) won the first European approval for its targeted breast cancer drug Perjeta as Swiss regulators cleared the treatment for sale. Report
> Korean drugmakers are looking to expand geographically as government price cuts roll into effect. Report
> Stanford University demanded that the dermatology specialist Nu Skin stop using one of its researcher's names in its promotional materials. Report
@FierceMedDev: Teleflex has closed the $45.2M sale of its ortho unit to Tecomet. News | Follow @FierceMedDev
@MarkHFierce: We have a great roster of new stories this week in FierceBiotechResearch. Check them out! More | Follow @MarkHFierce
@DamianFierce: Teleflex has closed the $45.2M sale of its ortho unit to Tecomet. News | Follow @DamianFierce
> Indiana officials say device tax will hamstring state industry. Report
> Crowded market could blunt profits for hypertension techs. More
> FDA demands 3-year study of St. Jude's leads. Article
Biotech News
@FierceBiotech: Geron generates spark from cancer pipeline. News | Related report by @MarkHFierce: Report | Follow @FierceBiotech
@JohnCFierce: CRO market headed to $1B in India according to Frost & Sullivan. Report | Follow @JohnCFierce
@RyanMFierce: Yes, the Farber doc did say "mouse's mojo." But the study of rodents', ah, zest could pave way to "the pill" for guys. More | Follow @RyanMFierce
> Gene patent ruling seen as win for Myriad, biotech industry. Story
> Harvard docs happen upon potential male birth control with cancer compound. Article
> Quintiles cozies up to Eli Lilly with new Indy office. Story
> GSK runs to PhIII with upbeat data on drug for severe asthma. More
And Finally... A U.S. appeals court reaffirmed its ruling that human genes can be patented. Report